Hussman Strategic Advisors Inc. Sells 10,500 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Hussman Strategic Advisors Inc. decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 25.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,500 shares of the specialty pharmaceutical company’s stock after selling 10,500 shares during the period. Hussman Strategic Advisors Inc. owned about 0.10% of Collegium Pharmaceutical worth $902,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Penserra Capital Management LLC bought a new position in shares of Collegium Pharmaceutical during the third quarter valued at $757,000. Barclays PLC raised its stake in shares of Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after acquiring an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 10.7% during the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $695,000 after acquiring an additional 1,731 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 35,439 shares during the last quarter.

Collegium Pharmaceutical Trading Down 0.5 %

COLL opened at $29.75 on Friday. Collegium Pharmaceutical, Inc. has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a fifty day moving average of $31.00 and a 200-day moving average of $33.72. The stock has a market cap of $959.44 million, a PE ratio of 12.82 and a beta of 0.82.

Wall Street Analyst Weigh In

COLL has been the subject of several analyst reports. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.98% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.